两部门提出16条措施支持创新药高质量发展

Core Viewpoint - The National Healthcare Security Administration and the National Health Commission have issued 16 measures to support the high-quality development of innovative drugs, which will play a significant role in the industry [1] Group 1: Support for Innovative Drug Development - The measures aim to create a new landscape for innovative drug research and development that is oriented towards clinical value, stimulating R&D vitality through various supports such as healthcare data, investment encouragement, and national science and technology projects [1] - The implementation of a directory access policy and guidance will help align innovative drug development with clinical treatment needs [1] Group 2: Multi-Payment System for Innovative Drugs - A multi-payment system for innovative drugs will be established to broaden payment channels, including regular adjustments to the healthcare insurance directory to include eligible innovative drugs at reasonable prices [1] - The introduction of a commercial health insurance directory for innovative drugs will enhance the multi-layered medical security system and improve payment capabilities [1] Group 3: Accessibility of Innovative Drugs - The measures propose practical policies to enhance the accessibility of innovative drugs, addressing concerns related to their use across various stages such as listing, hospitalization, payment, and distribution [1] - Encouragement for the rational use of innovative drugs is emphasized to improve their availability in the market [1]